---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039759"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:44:19.431190+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Personalis Q2 revenue $16.7M (-8% YoY); net loss $24.0M; tightens FY guidance to $70-72M

## Summary
- Total revenue $16.7M vs $18.2M in Q2 2022, an 8% decrease; pharma/enterprise revenue $13.7M, down 3%.
- Net loss $24.0M ($0.50 EPS) vs $24.8M loss in Q2 2022; cash and investments $137.2M as of June 30.
- FY 2023 revenue guidance tightened to $70M-$72M; net loss expected ~$103M, cash usage ~$70M.
- VA MVP exercised first of four one-year renewal options; second patent lawsuit filed against Foresight Diagnostics.
- Announced collaboration with National Cancer Center Hospital East and Ono Pharmaceutical for rectal cancer biomarker analysis.

## SEC filing metadata
- accession: 0000950170-23-039759
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/0000950170-23-039759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/psnl-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039759
- JSON: https://secwatch.observer/filing/0000950170-23-039759.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039759.txt

## Key facts
- Earnings Releases
  Personalis, Inc. reported second quarter ended June 30, 2023 results: revenue $16.7 million, net income $24.0 million, EPS $0.50.
  - Period: second quarter ended June 30, 2023
  - Revenue: $16.7 million
  - Net income: $24.0 million
  - EPS: $0.50
  - Result: reported results
  source text: evidence, we are paving the way for our successful entry into the clinical diagnostics market.” Second Quarter Financial Highlights • Reported total company revenue of $16.7 million for the second quarter of 2023, representing an 8% decrease compared with $18.2 million for the second quarter of 2022 o Revenue from pharma tests, enterprise sales, and other
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000095017023039759/0000950170-23-039759-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.